It was proven that YKL-40 causes up-regulation of VEGF expression and new tumour vasculature induced by YKL-40 is partially dependent on VEGF [62]; therefore, targeted treatments against YKL-40 could affect GB’s treatment. The gene discussed is CHI3L1; the disease is neoplasm.